The company's test uses self-collected saliva samples from potential parents to assess their future child's genetic predisposition to various diseases.
The financing will go toward the expansion of the company's laboratory operations and acceleration of the sales and marketing efforts of its Syn-One Test.
The firm said it has developed a POC test that uses a biomarker for HPV16, which is responsible for more than 90 percent of all HPV-related head and neck tumors.
The company offers a digital platform designed to simplify genetic test ordering and results reporting, and recently launched a workflow for COVID-19 testing.
Paige said it will use the financing to expand its geographic footprint as it accelerates the development of artificial intelligence-based clinical applications, biomarkers, and diagnostic tests.
The company is using the funds to develop a blood-based test that uses infrared spectroscopy and artificial intelligence for early-stage cancer detection.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
